ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IGMS IGM Biosciences Inc

9.97
-1.50 (-13.08%)
Last Updated: 20:35:38
Delayed by 15 minutes
Share Name Share Symbol Market Type
IGM Biosciences Inc NASDAQ:IGMS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50 -13.08% 9.97 9.95 10.00 11.595 9.89 11.51 466,943 20:35:38

IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03/01/2024 12:00pm

GlobeNewswire Inc.


IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more IGM Biosciences Charts.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

About IGM Biosciences, Inc.IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact:Argot PartnersDavid Pitts212-600-1902igmbio@argotpartners.com

1 Year IGM Biosciences Chart

1 Year IGM Biosciences Chart

1 Month IGM Biosciences Chart

1 Month IGM Biosciences Chart